Results

1–10 of 120 results for Age-Related Macular Degeneration

Short-term Effects of COVID-19-Related Deferral of Intravitreal Injection Visits
William E. Smiddy, MD
Annual Meeting Talks
2021
Geographic Access Disparities of Clinical Trials in Neovascular Age-Related Macular Degeneration in the United States
Rebecca Soares, MD
Annual Meeting Talks
2021
Faricimab in Neovascular Age-Related Macular Degeneration: Week 48 Efficacy, Safety, and Durability Results From the Phase 3 TENAYA and LUCERNE Trials
Karl G. Csaky, MD, PhD
Annual Meeting Talks
2021
Analysis of Retinal Fluid and Vision Outcomes in the Archway Phase 3 Trial of the Port Delivery System With Ranibizumab (PDS) in Patients With nAMD
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2021
Key Pearls of Conjunctival and Tenon’s Capsule Handling During the Implant Insertion Procedure for the Port Delivery System With Ranibizumab (PDS)
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2021
Evaluating ANX007, a Novel C1q Inhibitor, in the Treatment of Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration: The ARCHER Study
Nancy M. Holekamp, MD, FASRS
Annual Meeting Talks
2021
Key Pearls of the Refill-Exchange Procedure for the Port Delivery System With Ranibizumab (PDS)
Jordan M. Graff, MD, FACS
Annual Meeting Talks
2021
Intravitreal Anti-VEGF Therapy in Maintaining Long-term Driving Vision in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Parisa Emami Naeini, MD, MPH
Annual Meeting Talks
2021
Real World Experience of Brolucizumab for Persistent Macular Fluid in Neovascular Age-Related Macular Degeneration After Prior Anti-VEGF Treatments
Rehan M. Hussain, MD
Annual Meeting Talks
2021
Clinical and Demographic Factors Associated With Loss to Follow-up in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Durga Borkar, MD
Annual Meeting Talks
2021